Cargando…
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
BACKGROUND: Glatiramer acetate (GA) and interferon-beta (IFN-β) are disease-modifying therapies (DMTs) for multiple sclerosis that are administered through subcutaneous (SC) or intramuscular (IM) injections. Skin reactions associated with DMTs are common and may influence patient’s health-related qu...
Autores principales: | Balak, Deepak MW, Hengstman, Gerald JD, Hajdarbegovic, Enes, van den Brule, Rob JP, Hupperts, Raymond MM, Thio, Hok Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854544/ https://www.ncbi.nlm.nih.gov/pubmed/24131589 http://dx.doi.org/10.1186/1471-2377-13-146 |
Ejemplares similares
-
Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis
por: Balak, Deepak MW, et al.
Publicado: (2011) -
Drug-induced psoriasis: clinical perspectives
por: Balak, Deepak MW, et al.
Publicado: (2017) -
The Association between Atopic Disorders and Keloids: A Case-control Study
por: Hajdarbegovic, Enes, et al.
Publicado: (2015) -
Atopy in cutaneous and arthropatic psoriasis
por: Hajdarbegovic, E, et al.
Publicado: (2010) -
Treatment of lupus erythematosus with fumaric acid ester derivatives: two case-reports
por: Balak, Deepak MW, et al.
Publicado: (2011)